Incidence and Epidemiology of Heart Failure
- MD William B. Kannel
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Epidemiologic data from the Framingham Study provide insights into the population burden of heart failure (CHF), its prognosis and modifiable risk factors that promote it. In the general population CHF is chiefly the end stage of hypertensive, coronary and valvular cardiovascular disease. It is a major and growing problem in most affluent countries because of aging populations of increased size, and the prolongation of the lives of cardiac patients by modern therapy. Once clinically manifest, CHF, despite recent innovations in therapy, carries an unacceptably high mortality rate. In the Framingham Study, median survival is only 1.7 y for men and 3.2 y for women, with only 25% of men and 38% of women surviving 5 y. This is a mortality rate 4–8 times that of the general population of the same age. This poor outlook is observed for all etiologies of CHF and sudden death is a prominent feature of the mortality. Based on population attributable risks, hypertension has the greatest impact, accounting for 39% of CHF events in men and 59% in women. Despite its much lower prevalence in the population (3–10%) myocardial infarction also has a high attributable risk in men (34%) and women (13%). Valvular heart disease only accounted for 7–8% of CHF. Hypertension increased the age and risk factor adjusted hazard of CHF 2-fold in men and 3-fold in women, with a greater impact of the systolic than diastolic blood pressure. Diabetes increased CHF risk 2–8 fold with risk ratios twice as large in women as men. About 19% of CHF cases have diabetes. It accounted for 6–12% of the CHF in the Framingham Study cohort. Dyslipidemia characterized by a high total/HDL cholesterol ratio, but not the total cholesterol alone was a risk factor for CHF. An enlarged heart on X-Ray, ECG-LVH, a reduced vital capacity and rapid heart rate usually signified deteriorating cardiac function. CHF risk associated with ECG-LVH was independent of X-Ray cardiomegaly but risk was further augmented when both coexist. Echocardiographic left ventricular hypertrophy signifies a high risk of CHF proportional to the degree of increase in left ventricular mass without a critical value that delineates compensatory from pathological hypertrophy. Risk of CHF in persons predisposed by hypertension, diabetes or cardiac conditions varies over a 10-fold range depending on the aforementioned modifiable risk factors and indicators of deteriorating left ventricular function. Using multivariate risk formulations it is possible to identify 20% of the population from which 70% of the CHF will evolve. Those in the upper quintile of multivariate risk are good candidates for echocardiographic testing to delineate those needing aggressive preventive measures to delay the onset of CHF. Therapy of CHF must begin with treatment of presymptomatic left ventricular dysfunction to reverse the dysfunctional maladaptive changes.
- Kannel, WB, Belanger, AJ. (1991) Epidemiology of heart failure. American Heart J 121: pp. 951-957
- Effect of Enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New Eng J Med. 327: pp. 685-691
- National Center for Health Statistics: Health, United States. 1995 DHHS No. (PHS) 96-1232. US Govt. Printing Office, 1996.
- National Heart, Lung, and Blood Institute: Morbidity and Mortality Chartbook on Cardiovascular Lung and Blood Diseases. 1996. US Dept. of Health and Human Services.
- Gillum, RF. (1993) Epidemiology of heart failure in the United States. Amer Heart J 126: pp. 1042-1047
- Ho, KKL, Anderson, KM, Kannel, WB, Grossman Wand Levy, D. (1993) Survival after the onset of heart failure in Framingham Heart Study subjects. Circ 88: pp. 107-115
- Graves, EG, Gillum, BS:. (1996) 1994 Summary: National Hospital Discharge Survey: Advance Data 278: pp. 1-12
- Ranofsky A. Inpatient utilization of short stay hospitalizations by diagnosis. United States. 1971;National center for Health Statistics. DHEW Pub No. (HRA) 75-1767;1974.
- Brown, AM, Cleland, JGF. (1998) Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J. 19: pp. 1063-1069
- McMurray, J, McDonough, T, Morrison, CE (1993) Trends for hospitalization for heart failure in Scotland. 1980-1990. Eur Heart J 14: pp. 1158-1162
- Levy, D, Larson, MG, Vasan, RS, Kannel, WB, Ho, KKL. (1996) The progression from hypertension to congestive heart failure. JAMA 275: pp. 1557-1562
- Kannel, WB, Ho, KKL, Thom, T. (1995) Changing epidemiological features of cardiac failure. Brit Heart J 72: pp. S3-S9
- Ho, KKL, Pinsky, JL, Kannel, WB, Levy, D. (1993) The epidemiology of heart failure: The Framingham Study. J AM Coll Cardiol 22: pp. 6a-13a
- National Heart Lung and Blood Institute. Data Fact Sheet: Congestive Heart Failure in the United States: A New Epidemic. NHLBI Information center. P.O. Box 30105. Bethesda MD. 20804-0101. 1996.
- Brophy, JM. (1992) Epidemiology of congestive heart failure: Canadian data from 1970 to 1989. Can J Cardiol 8: pp. 495-498
- Ghandi, MM. (1997) Clinical epidemiology of coronary heart disease in the UK. Br J Hosp Med 58: pp. 23-27
- Effect of enalapril on mortality in severe congestive heart failure. Results of the cooperative Scandinavian Enalapril Survival Study. N Engl J Med 316: pp. 1429-1435
- Effect of Rampiril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: pp. 821-828
- Gillum, RF. (1986) Idiopathic cardiomyopathy in the United States, 1970-1982. Am Heart J 111: pp. 752-755
- Sugrue, DD, Rodeheffer, RJ, Codd, MB, Ballard, DJ, Fuster, V, Gersh, BJ. (1992) The clinical course of idiopathic dilated cardiomyopathy. Ann Intern Med 117: pp. 117-123
- Rakar, S, Simagra, G, Di Lenarda, A, Poletti, A, Bussani, R, Silvestri, F, Camerini, F. (1997) Epidemiology of dilated cardiomyopathy. A prospective postmortem study of 5252 necropsies. Eur Heart J 18: pp. 117-123
- Levine, SA. (1949) The value of determination of vital capacity of the lungs in the case of patients with heart disease. Arq Bras Cardiol 2: pp. 253
- Kannel, WB, D'Agostino, RB (1996) Use of vital capacity for cardiac failure risk estimation in persons with coronary disease and left ventricular hypertrophy. Am J Cardiol 77: pp. 1155-1158
- Gillman, MW, Kannel, WB, Belanger, A, D'Agostino, RB (1993) Influence of heart rate on mortality among persons with hypertension. The Framingham Study. Am Heart J 125: pp. 1148-1154
- Kannel, WB, Cupples, LA. (1988) Epidemiology and risk profile of cardiac failure. Cardiovasc Drugs and Therapy 2: pp. 387-395
- American Heart Association. 1997 Heart and Stroke: Statistical Update. Dallas TX.
- Incidence and Epidemiology of Heart Failure
Heart Failure Reviews
Volume 5, Issue 2 , pp 167-173
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- MD William B. Kannel (1) (2)
- Author Affiliations
- 1. Department of Preventive Medicine and Epidemiology, Evans Department of Clinical Research, Boston University School of Medicine, Boston, Massachusetts
- 2. ASTRA USA, Hoechst Marion Roussel and Servier Amérique, Inc., USA